Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 16/20 | 0.48 |
| ▸ | GUCY1A1 | Q02108 | 2/20 | 0.44 |
| ▸ | GUCY1B1 | Q02153 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29219152 | 0.99 | PDE5A (0.47) | PDE5AGUCY1A1GUCY1B1PIK3CD | |
| SCHEMBL18672347 | 0.89 | PDE5A (0.51) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL31630833 | 0.89 | PDE5A (0.51) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL20433911 | 0.89 | PIK3CD (0.42) | PDE5APIK3CDADORA3KCNH2 | |
| SCHEMBL29859628 | 0.88 | PDE5A (0.46) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL9913932 | 0.88 | PDE5A (0.46) | PDE5AGUCY1A1GUCY1B1 | |
| Hydrochloric Acid SCHEMBL14990786 | 0.87 | PDE5A (0.45) | PDE5AGUCY1A1GUCY1B1 | |
| Acetic Acid SCHEMBL428284 | 0.87 | PDE5A (0.48) | PDE5AGUCY1A1GUCY1B1ADORA3KCNH2 | |
| Formic Acid SCHEMBL30884591 | 0.86 | PDE5A (0.45) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL18672348 | 0.85 | PDE5A (0.46) | PDE5AGUCY1A1GUCY1B1ADORA3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637456-B2 | Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl} carbamate | ADVERIO PHARMA GMBH (DE) | 2026-05-26 | — | — | US | disclosed |
| CN-119954802-A | Process for preparing compounds | 阿德弗里奥药品有限责任公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119954803-A | Process for preparing compounds | 阿德弗里奥药品有限责任公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-115697978-B | Process for preparing methyl {4, 6-diamino-2- [ 5-fluoro-1- (2-fluorobenzyl) -1H-pyrazolo [3,4-b ] pyridin-3-yl ] pyrimidin-5-yl } carbamate | 阿德弗里奥药品有限责任公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20230219952-A1 | PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3 -YL]PYRIMIDIN-5-YL} CARBAMATE | ADVERIO PHARMA GMBH (DE) | 2023-07-13 | — | — | US | disclosed |
| US-20230219952-A1 | PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3 -YL]PYRIMIDIN-5-YL} CARBAMATE | ADVERIO PHARMA GMBH (DE) | 2023-07-13 | — | — | US | disclosed |
| US-20230219952-A1 | PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3 -YL]PYRIMIDIN-5-YL} CARBAMATE | ADVERIO PHARMA GMBH (DE) | 2023-07-13 | — | — | US | disclosed |
| EP-4165028-A1 | PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]PYRIMIDIN-5-YL}CARBAMATE | Adverio Pharma GmbH (DE) | 2023-04-19 | — | — | EP | disclosed |
| CN-115697978-A | Method for preparing methyl {4,6-diamino-2- [ 5-fluoro-1- (2-fluorobenzyl) -1H-pyrazolo [3,4-b ] pyridin-3-yl ] pyrimidin-5-yl } carbamate | 阿德弗里奥药品有限责任公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021254981-A1 | PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]PYRIMIDIN-5-YL}CARBAMATE | ADVERIO PHARMA GMBH (DE) | 2021-12-23 | — | — | WO | disclosed |
| US-20130143900-A1 | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-06 | — | — | US | disclosed |
| US-20130143900-A1 | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-06 | — | — | US | disclosed |
| US-20130143900-A1 | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-06 | — | — | US | disclosed |
| WO-2013030288-A1 | SUBSTITUTED ANNELLATED PYRIMIDINE AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-07 | — | — | WO | disclosed |
| WO-2012004258-A9 | RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012028647-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012028645-A1 | METHOD FOR THE PRODUCTION OF 5-FLUORO-1H-PYRAZOLO[3,4-B]PYRIDINE-3-CARBONITRILE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012028645-A1 | METHOD FOR THE PRODUCTION OF 5-FLUORO-1H-PYRAZOLO[3,4-B]PYRIDINE-3-CARBONITRILE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012028647-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012004258-A1 | RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637456-B2 | Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl} carbamate | POLL, F9, DNMT3B | PDE5A 445/4885GUCY1A1 952/4885GUCY1B1 635/4885 |
| US-20230219952-A1 | PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3 -YL]PYRIMIDIN-5-YL} CARBAMATE | POLL, DNMT3B, MTAP | PDE5A 429/4885GUCY1A1 1281/4885GUCY1B1 798/4885 |
| US-20130143900-A1 | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines | CYP3A5, CYP4F2, CYP2F1 | PDE5A 67/4885GUCY1A1 989/4885GUCY1B1 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.